US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>SpyGlass Pharma priced at $16.00 and closed day one at $26.40, up 65%, after opening 50% higher and trading to $32.44.</li>
<li>The deal was multiple-times oversubscribed, with strong participation from mutual funds and healthcare-dedicated investors supporting the aftermarket.</li>
<li>Med-Tech positioning and backing from top-tier investors—especially RA Capital—helped drive one of the strongest first-day IPO performances this cycle.</li>
</ul>


SpyGlass Pharma priced at $16.00 and closed day one at $26.40, up 65%, after opening 50% higher and trading to $32.44.
The deal was multiple-times oversubscribed, with strong participation from mutual funds and healthcare-dedicated investors supporting the aftermarket.
Med-Tech positioning and backing from top-tier investors—especially RA Capital—helped drive one of the strongest first-day IPO performances this cycle.


SpyGlass Pharma Inc (SGP): Med-Tech Vision Pays Off: SpyGlass Pharma IPO Pops on Day One

<ul>
<li>Channel checks indicate SpyGlass Pharma’s IPO is oversubscribed at launch, with interest from both new investors and existing shareholders.</li>
<li>Lead BIM-IOL System combines cataract surgery with long-acting drug delivery, addressing glaucoma adherence challenges through a streamlined, surgeon-friendly approach.</li>
<li>Backed by top-tier investors and advancing Phase 3 trials, SpyGlass presents a late-stage, differentiated healthcare IPO setup.</li>
</ul>


Channel checks indicate SpyGlass Pharma’s IPO is oversubscribed at launch, with interest from both new investors and existing shareholders.
Lead BIM-IOL System combines cataract surgery with long-acting drug delivery, addressing glaucoma adherence challenges through a streamlined, surgeon-friendly approach.
Backed by top-tier investors and advancing Phase 3 trials, SpyGlass presents a late-stage, differentiated healthcare IPO setup.


SpyGlass Pharma Inc (SGP): IPO Draws Demand as Med-Tech Story Gains Traction

Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

<ul><li>✅ IPO PROPHET RATING: 7.6/10 🏦 Deal Quality &amp; Underwriters: 8.2/10 Spyglass Therapeutics is preparing to list on the Nasdaq under the ticker SPYX as a clinical-stage biopharmaceutical company developing targeted therapies for chronic diseases with limited treatment options.</li><li>The company plans to offer 9.375 million shares at a price range of $15 to $17 per share, implying gross proceeds of approximately $150 million at the midpoint, before any overallotment.</li><li>At this level, Spyglass is entering the public markets with a sub-$1 billion equity valuation, placing it squarely within the mid-cap clinical biotech universe.</li></ul>

✅ IPO PROPHET RATING: 7.6/10 🏦 Deal Quality &amp; Underwriters: 8.2/10 Spyglass Therapeutics is preparing to list on the Nasdaq under the ticker SPYX as a clinical-stage biopharmaceutical company developing targeted therapies for chronic diseases with limited treatment options.The company plans to offer 9.375 million shares at a price range of $15 to $17 per share, implying gross proceeds of approximately $150 million at the midpoint, before any overallotment.At this level, Spyglass is entering the public markets with a sub-$1 billion equity valuation, placing it squarely within the mid-cap clinical biotech universe.

<ul>
<li>Spyglass Pharma, Inc .has set terms for its initial public offering, positioning the late-stage ophthalmology biotech to enter the public markets.</li>
<li>The company plans to offer 9.375 million shares at a proposed price range of $15.00 to $17.00 per share , raising approximately $150 million in gross proceeds at the $16.00 midpoint , before underwriting expenses.</li>
<li>At the midpoint, SpyGlass Pharma would carry an implied equity value of approximately $510 million, based on roughly 31.9 million shares outstanding following the offering.</li>
</ul>


Spyglass Pharma, Inc .has set terms for its initial public offering, positioning the late-stage ophthalmology biotech to enter the public markets.
The company plans to offer 9.375 million shares at a proposed price range of $15.00 to $17.00 per share , raising approximately $150 million in gross proceeds at the $16.00 midpoint , before underwriting expenses.
At the midpoint, SpyGlass Pharma would carry an implied equity value of approximately $510 million, based on roughly 31.9 million shares outstanding following the offering.


SpyGlass Pharma Sets Terms for IPO as Ophthalmology-Focused Biotech Advances Sustained-Release Platform

<ul>
<li>IPO Launch: SpyGlass Pharma (SGP US) filed for a 9.375 million-share IPO at $15–$17, aiming to debut on February 6th with a $467–$534 million market cap. </li>
<li>Lead Product &amp; Trials: Its BIM-IOL System delivers three years of bimatoprost via drug-eluting intraocular lenses during cataract surgery; two Phase 3 trials are underway.Use of Proceeds &amp;</li>
<li>IPO proceeds will fund trials, R&amp;D, and potential commercial launch; company backed by top-tier investors including NEA, RA Capital, and Vensana Capital.</li>
</ul>


IPO Launch: SpyGlass Pharma (SGP US) filed for a 9.375 million-share IPO at $15–$17, aiming to debut on February 6th with a $467–$534 million market cap. 
Lead Product &amp; Trials: Its BIM-IOL System delivers three years of bimatoprost via drug-eluting intraocular lenses during cataract surgery; two Phase 3 trials are underway.Use of Proceeds &amp;
IPO proceeds will fund trials, R&amp;D, and potential commercial launch; company backed by top-tier investors including NEA, RA Capital, and Vensana Capital.


SpyGlass Pharma, Inc. (SGP): Glaucoma Care Biotech Sets Terms for IPO, Joins Heavy Issuance Week

United States

Spyglass Pharma, Inc. operates as an ophthalmic biotechnology company. The company provides drug delivery platform, lasting treatment, and routine ophthalmic surgery. Spyglass Pharma serves glaucoma patients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

SpyGlass Pharma (SGP US)

SpyGlass Pharma Inc (SGP): Med-Tech Vision Pays Off: SpyGlass Pharma IPO Pops on Day One

SpyGlass Pharma's IPO priced at $16.00, closed at $26.40 (+65%), oversubscribed deal with strong investor support, backed by top-tier investors...

IPO Boutique

SpyGlass Pharma Inc (SGP): IPO Draws Demand as Med-Tech Story Gains Traction

SpyGlass Pharma's oversubscribed IPO offers innovative BIM-IOL System for cataract surgery with glaucoma treatment, backed by top investors and...

IPO Boutique

IPO Rating: Spyglass Pharma Inc.

✅ IPO PROPHET RATING: 7.6/10 🏦 Deal Quality & Underwriters: 8.2/10 Spyglass Therapeutics is preparing to list on the Nasdaq under the ticker...

IPO Prophet

SpyGlass Pharma Sets Terms for IPO as Ophthalmology-Focused Biotech Advances Sustained-Release Platform

Spyglass Pharma, Inc . has set terms for its initial public offering, positioning the late-stage ophthalmology biotech to enter the public...

IPO Prophet

SpyGlass Pharma, Inc. (SGP): Glaucoma Care Biotech Sets Terms for IPO, Joins Heavy Issuance Week

SpyGlass Pharma files for IPO to raise funds for their BIM-IOL System, aiming for a market cap of $467-$534 million with backing from top investors.

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

SpyGlass Pharma Inc (SGP): Med-Tech Vision Pays Off: SpyGlass Pharma IPO Pops on Day One

​SpyGlass Pharma's IPO priced at $16.00, closed at $26.40 (+65%), oversubscribed deal with strong investor support, backed by top-tier investors...

IPO Boutique

SpyGlass Pharma Inc (SGP): IPO Draws Demand as Med-Tech Story Gains Traction

​SpyGlass Pharma's oversubscribed IPO offers innovative BIM-IOL System for cataract surgery with glaucoma treatment, backed by top investors and...

IPO Boutique

IPO Rating: Spyglass Pharma Inc.

✅ IPO PROPHET RATING: 7.6/10 🏦 Deal Quality & Underwriters: 8.2/10 Spyglass Therapeutics is preparing to list on the Nasdaq under the ticker...

IPO Prophet

SpyGlass Pharma Sets Terms for IPO as Ophthalmology-Focused Biotech Advances Sustained-Release Platform

Spyglass Pharma, Inc . has set terms for its initial public offering, positioning the late-stage ophthalmology biotech to enter the public...

IPO Prophet

SpyGlass Pharma, Inc. (SGP): Glaucoma Care Biotech Sets Terms for IPO, Joins Heavy Issuance Week

​SpyGlass Pharma files for IPO to raise funds for their BIM-IOL System, aiming for a market cap of $467-$534 million with backing from top investors.

IPO Boutique

SpyGlass Pharma's IPO priced at $16.00, closed at $26.40 (+65%), oversubscribed deal with strong investor support, backed by top-tier investors...

SpyGlass Pharma's oversubscribed IPO offers innovative BIM-IOL System for cataract surgery with glaucoma treatment, backed by top investors and...

SpyGlass Pharma files for IPO to raise funds for their BIM-IOL System, aiming for a market cap of $467-$534 million with backing from top investors.